InvestorsHub Logo
Followers 468
Posts 26923
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Friday, 01/28/2011 12:28:04 PM

Friday, January 28, 2011 12:28:04 PM

Post# of 457
UPDATE 2-Canada's Angiotech to file for bankruptcy

Angiotech Pharmaceuticals, Inc.

Fri Jan 28, 2011 10:16am EST

* Says recapitalization deal to cut debt by $250 mln

* Deal supported by majority of subordinated noteholders

* Lines up $25 mln DIP loan

* Existing shareholders to be wiped out (Adds details of settlement with former stockholders of Quill Medical)

Jan 28 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO) said it will file for bankruptcy protection under Canada's Companies' Creditors Arrangement Act to cut $250 million of its debt.

All of the company's existing shareholders will be wiped out without any compensation under a proposed recapitalization deal. The transaction is supported by noteholders representing more than 84 percent of the outstanding subordinated notes.

The Vancouver-based company, a specialty pharmaceutical and medical device maker, has been hit hard by declining sales of its Taxus coronary stent systems.

Angiotech has also lined up a $25 million debtor-in-possession loan from Wells Fargo Capital Finance LLC to continue operations while under creditor protection.

Under the proposed plan, noteholders will exchange their subordinated notes for a share in 96 percent of the reorganized company's common stock, Angiotech said in a statement.

The company has also agreed to pay $6 million to former shareholders of Quill Medical Inc to settle a lawsuit filed last October.

The lawsuit alleged that Angiotech, which acquired Quill Medical in 2006, misrepresented or made omissions during negotiations for the merger. (Reporting by Santosh Nadgir in Bangalore; Editing by Sriraj Kalluvila and Gopakumar Warrier)


surf's up......crikey



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.